India, Aug. 7 -- Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEVTM, in combination with Nivolumab (Bristol Myers Squibb), for adults with unresectable advanced cutaneous melanoma who have progressed following anti-PD-1 antibody-based therapy.
Advanced melanoma patients often face limited treatment options, with more than half experiencing disease progression. Prognosis after progression is poor, with median overall survival typically less than one year.
TUDRIQEVTM (vusolimogene oderparepvec-wtpg) is an oncolytic immunotherapy designed to selectively replicate within tumors and stimulate an anti-tumor immune response. It is administered by intratumorl injection into superficial and dee...